Expertise in
1
conditions

Stefan N. Symeonides

Edinburgh, SCT, GB 
Expertise in
1
conditions
Edinburgh, SCT, GB 

Overview

Stefan Symeonides practices practicing medicine in Edinburgh, United Kingdom.

Mr. Symeonides is highly rated in 1 condition, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Major Depression, Delayed Growth, and Nephrectomy.

He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Edinburgh, SCT, United Kingdom
Other Locations
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, with Pembrolizumab, in Patients with Unresectable Stage III / IV Cutaneous Melanoma and with Stage IV NSCLC (PDL1≥ 50%)
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, with Pembrolizumab, in Patients with Unresectable Stage III / IV Cutaneous Melanoma and with Stage IV NSCLC (PDL1≥ 50%)
Enrollment Status: Terminated
Publish Date: March 20, 2025
Intervention Type: Biological
Study Drugs: GAd-PEV, MVA-PEV
Study Phase: Phase 1
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

47 Total Publications

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2026

Frequently Asked Questions about Stefan N. Symeonides

Is Stefan N. Symeonides a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Stefan N. Symeonides is classified as an Advanced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stefan N. Symeonides participate in research or clinical trials?

Yes. Stefan N. Symeonides has published 47 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Stefan N. Symeonides's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Symeonides's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile